Our team of neuroscientists have authored a number of scientific and opinion papers addressing a range of topics, from challenges in accelerating drug repurposing to evaluations of evidence surrounding dementia prevention strategies.
Repurposing Food and Drug Administration (FDA)-approved drugs for a new indicaton may offer an accelerated pathway for new treatments but is also fraught with significant commercial, regulatory and reimbursement challenges. The Alzheimer's Drug Discovery Foundation and the Michael J. Fox Foundation for Parkinson's Research convened an advisory panel in October 2013 to better understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegerative diseases. In the resulting paper, the foundations explore opportunities for philanthropy, industry and government to begin to address these challenges, promote policy changes and develop targeted funding strategies to accelerate drug repurposing.
Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T and Fillit HM. Overcoming obstacles for repurposing for neurodegenerative diseases. Annals of Clinical and Translational Neurology. Volume 1, Issue 7.
Increased knowledge about the biology of synaptic function has led to the development of novel cognitive-enhancing therapeutic strategies with the potential for increased efficacy and safety. This editorial highlights a diverse array of approaches currently being explored to target cognitive dysfunction due to aging and/or Alzheimer's disease.
Though lacking conclusive proof, decades of research suggests that specific approaches, including the consumption of coffee, may be effective in preventing age-related cognitive decline and Alzheimer's disease. Coffee and caffeine are known to enhance short-term memory and cognition, and some limited research suggests that long-term use may protect against cognitive decline or dementia.
Carman AJ, Dacks PA, Lane RF, Shineman DW and Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. Journal of Nutrition, Health and Aging. 2014 Apr;18(4):383-92.
This editorial, published in Nature Reviews Drug discovery, provides recommendations to scientists on the process of selecting and managing a contract with an external vendor (contract research organizations). Contract research organizations (CROs) are required by scientists to provide industry standard services for drug discovery and development programs. This editorial is the outcome of a one day advisory panel convened by the ADDF.
Lane RF, Friedman LG, Keith C, Braithwaite SP, Frearson JA, Lowe DA, Longo FM, Refolo L, Watterson DM, Tsaioun K, Shineman DW, Fillit HM (2013). Optimizing the use of CROs by academia and small companies. Nature Reviews Drug Discovery Vol.12;487-488
This meeting report from our 13th International Conference, entitled “Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery” provides an overview on a number of ADDF-funded programs.
Lane RF, Dacks PA, Shineman DW, Fillit HM. Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery. Alzheimer’s Res Ther. 2013 Feb 4;5(1):5.
This review condenses the available scientific evidence with practical information on the available sources and the research steps needed to prove the effectiveness of their use.
Dacks PA, Shineman DW, Fillit HM. Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease. J Nutr Health Aging. 2013 Mar;17(3):240-51.
This chapter summarizes the current landscape of therapeutic strategies that scientists are investigating for Alzheimer’s disease.
This meeting report from our 12th International Conference, entitled “Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias” provides an overview on a number of ADDF-funded programs.
In 2011, the ADDF convened an advisory panel of experts from academia, government and industry and produced a brochure and scientific publication highlighting best practices to improve the design and implementation of preclinical animal studies to ultimately improve the chances of success for new drugs in the clinic.
Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM. Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther. 2011 Sep 28;3(5):28.
Produced in collaboration with the Association for Frontotemporal Degeneration, this landscape analysis highlights research funding trends and gaps in funding for frontotemporal dementia and related conditions.
Walentas CD, Shineman DW, Horton AR, Boeve BF, Fillit HM. 2011. An analysis of global research funding for the frontotemporal dementias: 1998-2008. Alzheimers Dement. 2011 Mar;7(2):142-50.
This meeting report from our 11th International Conference, entitled “A diverse portfolio of novel drug discovery efforts for Alzheimer’s disease” provides an overview on a number of ADDF-funded programs.
Lee LH, Shineman DW, Fillit HM. 2010. A diverse portfolio of novel drug discovery efforts for Alzheimer’s disease: Meeting report from the 11th International Conference on Alzheimer’s Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA. Alzheimers Res Ther. 2(6):33
This review summarizes the scientific talks presented at the conference “Therapeutics for Cognitive Aging,” hosted by the New York Academy of Sciences and the Alzheimer’s Drug Discovery Foundation on May 15, 2009.
Shineman D.W., Salthouse T.A., Launer L.J., Hof P.R., Bartzokis G., Kleiman R., Luine V., Buccafusco J.J., Small G.W., Aisen P.S., Lowe D.A., Fillit H.M. 2010. Therapeutics for cognitive aging. Annals of the New York Academy of Sciences. 1191(S1): E1-E15
Fillit H, Nash DT, Shineman D. 2009. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke. Alzheimers Dement. 5(2): 149-53.
This tutorial outlines the major stages of the drug discovery and development process and was prodiced in collaboration with Alzforum
An analysis of progress of ADDF-funded programs through 2008.